Hexin Biotech
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Hexin Biotech - overview
Established
2020
Location
Changchun, Jilin, China
Primary Industry
Biotechnology
About
Hexin Biotech, based in Changchun, China, is dedicated to developing innovative cancer therapies through advanced biotechnology, focusing on unique DNA and RNA structures for targeted treatments. Founded in 2020, Hexin Biotech (Changchun) Limited specializes in biopharmaceuticals with a particular emphasis on cancer therapies. The company has executed 1 deal, with its most recent transaction occurring on February 10, 2026, involving venture funding from Changchun Equity Investment Fund Management. Hexin Biotech specializes in the development of innovative cancer therapies, with a strong focus on First-in-Class and Best-in-Class drugs that target unique structures of DNA, RNA, and their associated proteins.
Their flagship product is a novel anti-cancer drug aimed at quadri-stranded DNA, which is being actively tested in clinical trials. The company expects to commercialize its leading anti-cancer drug following the receipt of IND clinical approval in March 2025 and FDA approval in July 2025. Their clientele includes cancer treatment facilities and research institutions, primarily in North America and Asia. Hexin Biotech operates within a clinical development framework that relies on partnerships with healthcare institutions and pharmaceutical companies to commercialize its products.
Revenue is generated through structured agreements with healthcare providers, focusing on B2B transactions where hospitals and oncology centers purchase therapies directly from the company. The revenue model is designed to support ongoing research and development while facilitating the market introduction of advanced cancer treatments. Hexin Biotech plans to further advance its product line by launching additional cancer therapies in the coming years, with specific timelines and details to be announced. The company aims to expand its market presence into new regions, particularly targeting Europe and Southeast Asia by 2027.
The recent venture funding raised in February 2026 will be utilized to support these growth initiatives and enhance their research capabilities.
Current Investors
Changchun Equity Investment Fund Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.hexinbiotech.com
Verticals
Manufacturing
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.